Hematologic Malignancies Program ABSTRACT The goal of the Hematologic Malignancies (HM) Program is to improve outcomes and expand opportunities for patients with leukemia, Hodgkin and non-Hodgkin lymphoma, and multiple myeloma by integrating basic, translational, and clinical research through close collaborations among investigators in the Program. Research collaborations are facilitated through disease- and modality-specific research teams that meet regularly, including leukemia, lymphoma, multiple myeloma, transplant, immunotherapy, and gene therapy. Each of these teams works in an integrated manner and includes multi-disciplinary collaborators from the HM Program as well as from other Cancer Center programs and cores. The Themes of our program are the following: Theme 1: Identify key biological pathways and targeting strategies for hematologic malignancies. Theme 2: Develop novel therapeutic approaches for early-phase clinical testing. Theme 3: Advance translational research in hematopoietic cell transplantation (HCT) and adoptive cellular immunotherapy (ACIT). The HM Program improves public health both through its refinement of currently available treatment options for hematological malignancies and its advancement of novel therapies to the clinic, via an intensive Phase I/II investigational drug program. We are exploring multiple avenues of treatment ? chemotherapy, immunotherapy, gene therapy, targeted therapy, chimeric antigen receptor T cell therapy and HCT ? to improve patient cure rates and treatment tolerability throughout the disease course. Membership: 37 Program Members representing 8 basic and clinical departments Publications: 319 total. 29.2% intra-programmatic; 35.1% inter-programmatic; 45.5% inter-institutional Funding: $6,409,859 peer-reviewed; $3,670,074 of which is NCI funding

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beckman Research Institute/City of Hope
United States
Zip Code
Raz, Dan J; Wu, Geena X; Consunji, Martin et al. (2018) The Effect of Primary Care Physician Knowledge of Lung Cancer Screening Guidelines on Perceptions and Utilization of Low-Dose Computed Tomography. Clin Lung Cancer 19:51-57
Solomon, Ilana; Rybak, Christina; Van Tongeren, Lily et al. (2018) Experience Gained from the Development and Execution of a Multidisciplinary Multi-syndrome Hereditary Colon Cancer Family Conference. J Cancer Educ :
Tirughana, Revathiswari; Metz, Marianne Z; Li, Zhongqi et al. (2018) GMP Production and Scale-Up of Adherent Neural Stem Cells with a Quantum Cell Expansion System. Mol Ther Methods Clin Dev 10:48-56
Cheng, Chun-Ting; Qi, Yue; Wang, Yi-Chang et al. (2018) Arginine starvation kills tumor cells through aspartate exhaustion and mitochondrial dysfunction. Commun Biol 1:178
Cho, H; Ayers, K; DePills, L et al. (2018) Modelling acute myeloid leukaemia in a continuum of differentiation states. Lett Biomath 5:S69-S98
Wang, Dongrui; Aguilar, Brenda; Starr, Renate et al. (2018) Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity. JCI Insight 3:
Liu, Xuxiang; Cao, Minghui; Palomares, Melanie et al. (2018) Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts. Breast Cancer Res 20:127
Das, Sadhan; Reddy, Marpadga A; Senapati, Parijat et al. (2018) Diabetes Mellitus-Induced Long Noncoding RNA Dnm3os Regulates Macrophage Functions and Inflammation via Nuclear Mechanisms. Arterioscler Thromb Vasc Biol 38:1806-1820
Querfeld, Christiane; Leung, Samantha; Myskowski, Patricia L et al. (2018) Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile. Cancer Immunol Res 6:900-909
Petrossian, Karineh; Kanaya, Noriko; Lo, Chiao et al. (2018) ER?-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer. Oncotarget 9:27736-27751

Showing the most recent 10 out of 1396 publications